Valneva Austria GmbH
BiotechValneva Austria GmbH is a biotechnology company focused on Infectious Disease. Key products include IXCHIQ.
Valneva Austria GmbH at a Glance
- Fast trial execution (16 months median completion)
Valneva Austria GmbH's Key Drugs
Valneva Austria GmbH's core commercial portfolio centers on IXCHIQ, spanning Infectious Disease — its most strategically important drugs approved in the last 15 years.
Valneva Austria GmbH's Recent FDA Approvals
New NDA/BLA approvals for Valneva Austria GmbH over the last two years — novel drugs only, excluding generics and label supplements.
Valneva Austria GmbH's Therapeutic Areas
Valneva Austria GmbH's approved drugs and pipeline span 1 therapeutic area, led by Infectious Disease, across 2 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Valneva Austria GmbH's Top Competitors
Valneva Austria GmbH's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Merck, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Valneva Austria GmbH Pipeline Snapshot
Valneva Austria GmbH has 17 active clinical programs from ClinicalTrials.gov — 7 Phase 3, 5 Phase 2 and 5 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • IXCHIQ leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Infectious Disease pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 9/12 completed
- • Speed: 16 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2009-03-29
- Latest
- 2023-11-08
- Applications
- 2
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges